| Name | Title | Contact Details |
|---|
At the Y, our cause is strengthening the foundations of community.
We are a non-profit, Michigan-based company and a subsidiary of the Henry Ford Health System, one of the nation`s leading health care systems. We provide health plans for everyone -- individuals and companies of all sizes. Since 1960, we`ve partnered with leading doctors, hospitals, employers and community organizations to enhance the lives of those we touch. We offer six distinct health insurance lines: • Group Insured Commercial • Individual • Medicare • Medicaid • Self-Funded • Network Leasing HAP also provides: • Award-winning wellness programs • Community outreach • Digital health tools • Disease management services • Personalized customer service
Wellington Place is a North Olmsted, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Wellness Coaches USA is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Blue Bell, PA. To find more information about Wellness Coaches USA, please visit www.wellnesscoachesusa.com
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.